Sunil Krishnan

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy
    Sunil Krishnan
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 110:47-55. 2007
  2. doi request reprint Radiotherapy for hepatocellular carcinoma: an overview
    Sunil Krishnan
    Division of Radiation Oncology, M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 097, Houston, Texas 77030, United States
    Ann Surg Oncol 15:1015-24. 2008
  3. pmc Integrin αvβ3-targeted gold nanoshells augment tumor vasculature-specific imaging and therapy
    Huan Xie
    Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Texas Southern University, Houston, TX 77030, USA
    Int J Nanomedicine 6:259-69. 2011
  4. pmc A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease
    Punit Kaur
    Department of Pathology, Scott and White Memorial Hospital and Clinic and the Texas A and M Health Science Center, College of Medicine, Temple, TX 76504, USA
    BMC Cancer 12:120. 2012
  5. ncbi request reprint Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation
    Sunil Krishnan
    Department of Radiation Oncology, The University of Texas, M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 107:2589-96. 2006
  6. ncbi request reprint Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177
    Sunil Krishnan
    Department of Radiation Oncology, Mayo Clinic College of Medicine, Rochester, MN, USA
    Int J Radiat Oncol Biol Phys 65:1192-9. 2006
  7. ncbi request reprint Daily targeting of liver tumors: screening patients with a mock treatment and using a combination of internal and external fiducials for image-guided respiratory-gated radiotherapy
    Sunil Krishnan
    Department of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas 77030, USA
    Med Phys 34:4591-3. 2007
  8. pmc Nanoparticle-mediated thermal therapy: evolving strategies for prostate cancer therapy
    Sunil Krishnan
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Int J Hyperthermia 26:775-89. 2010
  9. pmc Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer
    Kuzhuvelil B Harikumar
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Cancer 127:257-68. 2010
  10. doi request reprint Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model
    Ajaikumar B Kunnumakkara
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Cancer 125:2187-97. 2009

Detail Information

Publications91

  1. ncbi request reprint Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy
    Sunil Krishnan
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 110:47-55. 2007
    ....
  2. doi request reprint Radiotherapy for hepatocellular carcinoma: an overview
    Sunil Krishnan
    Division of Radiation Oncology, M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 097, Houston, Texas 77030, United States
    Ann Surg Oncol 15:1015-24. 2008
  3. pmc Integrin αvβ3-targeted gold nanoshells augment tumor vasculature-specific imaging and therapy
    Huan Xie
    Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Texas Southern University, Houston, TX 77030, USA
    Int J Nanomedicine 6:259-69. 2011
    ..Active targeting of NSs to integrin αvβ3 offers the potential to increase accumulation preferentially in tumors and thereby enhance therapy efficacy...
  4. pmc A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease
    Punit Kaur
    Department of Pathology, Scott and White Memorial Hospital and Clinic and the Texas A and M Health Science Center, College of Medicine, Temple, TX 76504, USA
    BMC Cancer 12:120. 2012
    ..The reason for this aggressive phenotype is currently the focus of intensive research. However, progress is hampered by the lack of suitable TNBC cell model systems...
  5. ncbi request reprint Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation
    Sunil Krishnan
    Department of Radiation Oncology, The University of Texas, M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 107:2589-96. 2006
    ..Prognostic factors are inadequately defined for disease-free survival and overall survival in patients with LAPC who are receiving chemoradiation, so more definitive prognostic factors would be very useful for designing clinical trials...
  6. ncbi request reprint Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177
    Sunil Krishnan
    Department of Radiation Oncology, Mayo Clinic College of Medicine, Rochester, MN, USA
    Int J Radiat Oncol Biol Phys 65:1192-9. 2006
    ..To evaluate the toxicity and maximum tolerated dose (MTD) of erlotinib plus radiation therapy (RT) in patients with glioblastoma multiforme (GBM) in a multicenter phase I trial...
  7. ncbi request reprint Daily targeting of liver tumors: screening patients with a mock treatment and using a combination of internal and external fiducials for image-guided respiratory-gated radiotherapy
    Sunil Krishnan
    Department of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas 77030, USA
    Med Phys 34:4591-3. 2007
    ..This technique could screen patients for gated therapy, reduce setup inaccuracy, and possibly individualize treatment margins...
  8. pmc Nanoparticle-mediated thermal therapy: evolving strategies for prostate cancer therapy
    Sunil Krishnan
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Int J Hyperthermia 26:775-89. 2010
    ..This review will also focus on the evolving strategies to improve the therapeutic index of prostate cancer treatment using nanoparticle-mediated hyperthermia...
  9. pmc Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer
    Kuzhuvelil B Harikumar
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Cancer 127:257-68. 2010
    ..Overall our results demonstrate that resveratrol can potentiate the effects of gemcitabine through suppression of markers of proliferation, invasion, angiogenesis and metastasis...
  10. doi request reprint Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model
    Ajaikumar B Kunnumakkara
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Cancer 125:2187-97. 2009
    ..Overall, our results suggest that curcumin sensitizes CRC to the antitumor and antimetastatic effects of capecitabine by suppressing NF-kappaB cell signaling pathway...
  11. doi request reprint Hyperfractionated accelerated radiotherapy for rectal cancer in patients with prior pelvic irradiation
    Prajnan Das
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Int J Radiat Oncol Biol Phys 77:60-5. 2010
    ..To retrospectively determine rates of toxicity, freedom from local progression, and survival in rectal cancer patients treated with reirradiation...
  12. ncbi request reprint Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of vater
    Sunil Krishnan
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Int J Radiat Oncol Biol Phys 70:735-43. 2008
    ..We retrospectively compared treatment outcomes in patients treated with pancreaticoduodenectomy alone versus those who received additional adjuvant CRT...
  13. doi request reprint Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial
    Prajnan Das
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas Electronic address
    Int J Radiat Oncol Biol Phys 88:301-5. 2014
    ..The goal of this phase 1 trial was to determine the maximum tolerated dose (MTD) of concurrent capecitabine, bevacizumab, and erlotinib with preoperative radiation therapy for rectal cancer...
  14. doi request reprint Intensity-modulated radiation therapy with concurrent chemotherapy as preoperative treatment for localized gastric adenocarcinoma
    Twisha Chakravarty
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 83:581-6. 2012
    ....
  15. ncbi request reprint Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer
    Sunil Krishnan
    Department of Radiation Oncology, The University of Texas, M D Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 66:762-71. 2006
    ..The aim of this study was to determine the efficacy of capecitabine (Xeloda), an oral fluoropyrimidine, as a radiosensitizer in the neoadjuvant treatment of locally advanced rectal cancer (LARC)...
  16. ncbi request reprint Patterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancer
    Tse Kuan Yu
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 71:1175-80. 2008
    ..To identify patterns of locoregional recurrence in patients treated with surgery and preoperative or postoperative radiotherapy or chemoradiation for rectal cancer...
  17. pmc Ursolic acid inhibits growth and metastasis of human colorectal cancer in an orthotopic nude mouse model by targeting multiple cell signaling pathways: chemosensitization with capecitabine
    Sahdeo Prasad
    Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 18:4942-53. 2012
    ..The effect of ursolic acid on the growth and chemosensitization was also examined in orthotopically implanted CRC in nude mice...
  18. pmc Concurrent capecitabine and upper abdominal radiation therapy is well tolerated
    Prajnan Das
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, USA
    Radiat Oncol 1:41. 2006
    ..Therefore, capecitabine and concurrent radiotherapy to the upper abdomen appears to be well tolerated. Capecitabine may serve as an alternative to bolus or infusional 5-FU during chemoradiation for upper gastrointestinal malignancies...
  19. doi request reprint Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer
    Christopher H Crane
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 76:824-30. 2010
    ..We designed this Phase II trial to assess the efficacy and safety of the addition of bevacizumab to concurrent neoadjuvant capecitabine-based chemoradiation in locally advanced rectal cancer...
  20. doi request reprint Reproducibility and genital sparing with a vaginal dilator used for female anal cancer patients
    Tina Marie Briere
    Department of Radiation Physics, UT MD Anderson Cancer Center, Houston, TX 77030, United States
    Radiother Oncol 104:161-6. 2012
    ..A vaginal dilator may help delineate and displace the vulva and lower vagina away from the primary tumor. The goal of this study was to evaluate the positional reproducibility and vaginal sparing with the use of a vaginal dilator...
  21. pmc Zyflamend suppresses growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model through modulation of multiple targets
    Ajaikumar B Kunnumakkara
    Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Int J Cancer 131:E292-303. 2012
    ....
  22. pmc Sacral insufficiency fractures after preoperative chemoradiation for rectal cancer: incidence, risk factors, and clinical course
    Michael P Herman
    Department of Radiation Oncology, UT MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 74:818-23. 2009
    ..Our goal was to determine the incidence, risk factors, and clinical course of SI fractures in patients treated with preoperative chemoradiation for rectal cancer...
  23. doi request reprint Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products
    Ajaikumar B Kunnumakkara
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:2128-36. 2008
    ..Because curcumin, a component of turmeric (Curcuma longa), has been shown to suppress NF-kappaB activation, whether it can sensitize the colorectal cancer to gamma-radiation was investigated in colorectal cancer xenografts in nude mice...
  24. ncbi request reprint Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis
    Prajnan Das
    Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 66:1378-83. 2006
    ....
  25. pmc {Gamma}-tocotrienol inhibits pancreatic tumors and sensitizes them to gemcitabine treatment by modulating the inflammatory microenvironment
    Ajaikumar B Kunnumakkara
    Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 70:8695-705. 2010
    ..Overall, our findings suggest that γ-T3 can inhibit the growth of human pancreatic tumors and sensitize them to gemcitabine by suppressing NF-κB-mediated inflammatory pathways linked to tumorigenesis...
  26. ncbi request reprint Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer
    Prajnan Das
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:1750-5. 2007
    ..The objective of this study was to identify predictive factors for pathologic complete response and tumor downstaging after preoperative chemoradiation for rectal cancer...
  27. ncbi request reprint Duodenal toxicity after fractionated chemoradiation for unresectable pancreatic cancer
    Patrick Kelly
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Int J Radiat Oncol Biol Phys 85:e143-9. 2013
    ..In order to guide future studies, we analyzed the clinical and dosimetric factors associated with duodenal toxicity in patients undergoing fractionated chemoradiation for LAPC...
  28. pmc Neoadjuvant treatment response as an early response indicator for patients with rectal cancer
    In Ja Park
    The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1402, USA
    J Clin Oncol 30:1770-6. 2012
    ..The purpose of this study was to assess and compare oncologic outcomes associated with the degree of pathologic response after chemoradiotherapy...
  29. doi request reprint Radiation treatment outcomes for unresectable hepatocellular carcinoma
    Heath D Skinner
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Acta Oncol 50:1191-8. 2011
    ..Data regarding the use of radiotherapy is limited in patients from populations without endemic viral hepatitis. We examine the outcomes for patients treated with radiotherapy in the modern era at a single institution...
  30. pmc Local excision after preoperative chemoradiation results in an equivalent outcome to total mesorectal excision in selected patients with T3 rectal cancer
    Glenda G Callender
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 17:441-7. 2010
    ..At nearly 4 years' follow-up, no difference in outcome was observed. This study compares outcomes in a larger cohort of patients and reevaluates the original 26 patients after longer follow-up...
  31. pmc Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression
    Christopher H Crane
    Dept of Radiation Oncology, Unit 97, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX
    J Clin Oncol 29:3037-43. 2011
    ..This phase II trial was designed to assess the efficacy and safety of cetuximab, gemcitabine, and oxaliplatin followed by cetuximab, capecitabine, and radiation therapy in locally advanced pancreatic cancer (LAPC)...
  32. doi request reprint Chemoradiation therapy for potentially resectable gastric cancer: clinical outcomes among patients who do not undergo planned surgery
    Michelle M Kim
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 71:167-72. 2008
    ....
  33. pmc Metformin use and improved response to therapy in rectal cancer
    Heath D Skinner
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center Houston, Texas, 77030
    Cancer Med 2:99-107. 2013
    ..013) and overall survival (P = 0.008) compared with other diabetic patients. Metformin use is associated with significantly higher pCR rates as well as improved survival. These promising data warrant further prospective study...
  34. ncbi request reprint Clinical benefit of palliative radiation therapy in advanced gastric cancer
    Michelle M Kim
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Acta Oncol 47:421-7. 2008
    ..Local progression of advanced gastric cancer often manifests as bleeding, dysphagia/obstruction, or pain. We evaluated the magnitude and durability of palliation with radiotherapy (RT)...
  35. pmc Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 16:836-47. 2009
    ..We evaluated long-term survival and patterns of recurrence in patients treated for PC with contemporary staging and multimodality therapy...
  36. pmc Number of lymph nodes examined and prognosis among pathologically lymph node-negative patients after preoperative chemoradiation therapy for rectal adenocarcinoma
    Chiaojung Jillian Tsai
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 117:3713-22. 2011
    ....
  37. doi request reprint Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head
    Gauri R Varadhachary
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 426, Houston, TX 77030, USA
    J Clin Oncol 26:3487-95. 2008
    ..We conducted a phase II trial of preoperative gemcitabine and cisplatin chemotherapy in addition to chemoradiation (Gem-Cis-XRT) and pancreaticoduodenectomy (PD) for patients with stage I/II pancreatic adenocarcinoma...
  38. doi request reprint Incidence, natural history, and patterns of locoregional recurrence in gastric cancer patients treated with preoperative chemoradiotherapy
    Valerie K Reed
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 71:741-7. 2008
    ..To retrospectively determine the incidence and patterns (in-field, marginal, or out-of-field) of locoregional gastric cancer recurrence in patients who received preoperative chemoradiotherapy and to determine the outcome in these patients...
  39. ncbi request reprint Improving soft-tissue contrast in four-dimensional computed tomography images of liver cancer patients using a deformable image registration method
    He Wang
    Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 72:201-9. 2008
    ..To investigate a deformable image registration method to improve soft-tissue contrast in four-dimensional (4D) computed tomography (CT) images of the liver...
  40. pmc Temporal patterns of fatigue predict pathologic response in patients treated with preoperative chemoradiation therapy for rectal cancer
    Hee Chul Park
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Int J Radiat Oncol Biol Phys 75:775-81. 2009
    ..To investigate whether symptom burden before and during preoperative chemoradiation therapy (CRT) for rectal cancer predicts for pathologic tumor response...
  41. pmc Boswellic acid inhibits growth and metastasis of human colorectal cancer in orthotopic mouse model by downregulating inflammatory, proliferative, invasive and angiogenic biomarkers
    Vivek R Yadav
    Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Cancer 130:2176-84. 2012
    ..Thus, our findings suggest that this boswellic acid analog can inhibit the growth and metastasis of human CRC in vivo through downregulation of cancer-associated biomarkers...
  42. pmc A novel small-molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vitro and in vivo
    Kuzhuvelil B Harikumar
    Department of Experimental Therapeutics, The UT MD Anderson Cancer Center, Houston, Texas, USA
    Mol Cancer Ther 9:1136-46. 2010
    ..Our results show for the first time that a PKD-specific small-molecule inhibitor CRT0066101 blocks pancreatic cancer growth in vivo and show that PKD is a novel therapeutic target in pancreatic cancer...
  43. ncbi request reprint Predictors and patterns of recurrence after definitive chemoradiation for anal cancer
    Prajnan Das
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 68:794-800. 2007
    ..To evaluate patterns of locoregional failure, and predictors of recurrence and survival in patients treated with chemoradiation for anal cancer...
  44. pmc Sesamin manifests chemopreventive effects through the suppression of NF-kappa B-regulated cell survival, proliferation, invasion, and angiogenic gene products
    Kuzhuvelil B Harikumar
    Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Mol Cancer Res 8:751-61. 2010
    ..Overall, our results showed that sesamin may have potential against cancer and other chronic diseases through the suppression of a pathway linked to the NF-kappaB signaling...
  45. pmc Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177
    Paul D Brown
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 26:5603-9. 2008
    ..Erlotinib, a selective EGFR inhibitor, was combined with temozolomide (TMZ) and radiotherapy (RT) in a phase I/II trial...
  46. pmc Inhibition of radiation-induced DNA repair and prosurvival pathways contributes to vorinostat-mediated radiosensitization of pancreatic cancer cells
    Amit Deorukhkar
    Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Pancreas 39:1277-83. 2010
    ....
  47. doi request reprint Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone
    Yerko Borghero
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 97, Houston, TX 77030, USA
    Ann Surg Oncol 15:3147-56. 2008
    ....
  48. ncbi request reprint Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy
    Atin Agarwal
    Department of Pathology, Baylor College of Medicine, Houston, Texas
    Cancer 119:4231-41. 2013
    ..The current study was conducted to determine whether quantified pathologic response assessed as a percentage of residual tumor cells is predictive of recurrence-free survival (RFS) in patients with rectal cancer...
  49. pmc Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing constitutive and inducible NF-kappaB activity
    Santosh K Sandur
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 75:534-42. 2009
    ..Simultaneous inhibition of these pathways can sensitize these tumors to radiation therapy...
  50. doi request reprint Intensity-modulated radiation therapy for the treatment of squamous cell anal cancer with para-aortic nodal involvement
    Joseph C Hodges
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 75:791-4. 2009
    ....
  51. pmc Modulation of in vivo tumor radiation response via gold nanoshell-mediated vascular-focused hyperthermia: characterizing an integrated antihypoxic and localized vascular disrupting targeting strategy
    Parmeswaran Diagaradjane
    Department of Experimental Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Nano Lett 8:1492-500. 2008
    ..This novel integrated antihypoxic and localized vascular disrupting therapy can potentially be combined with other conventional antitumor therapies...
  52. ncbi request reprint 4D-CT imaging with synchronized intravenous contrast injection to improve delineation of liver tumors for treatment planning
    A Sam Beddar
    Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, TX 77030, USA
    Radiother Oncol 87:445-8. 2008
    ..Combined 4D-CT imaging with synchronized IV contrast allows for both enhancement of tumor contrast and coverage over the entire breathing cycle...
  53. pmc Intensity modulated radiation therapy (IMRT): differences in target volumes and improvement in clinically relevant doses to small bowel in rectal carcinoma
    Henry Mok
    Department of Radiation Oncology, The University of Texas, M, d, Anderson Cancer Center, Houston, Texas, USA
    Radiat Oncol 6:63. 2011
    ..Therefore, we performed a comprehensive dosimetric evaluation of IMRT compared to 3-dimensional conformal radiation therapy (3DCRT) in standard, preoperative treatment for rectal cancer...
  54. ncbi request reprint Hepatic yttrium-90 radioembolotherapy in metastatic colorectal cancer treated with cetuximab or bevacizumab
    Ravi Murthy
    Department of Diagnostic Radiology, Interventional Radiology Section, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    J Vasc Interv Radiol 18:1588-91. 2007
    ..This report briefly describes the authors' treatment experience with this cohort of patients...
  55. doi request reprint Respiratory gating with EPID-based verification: the MDACC experience
    Tina Marie Briere
    Department of Radiation Physics, MD Anderson Cancer Center, Houston, TX 77030, USA
    Phys Med Biol 54:3379-91. 2009
    ..Daily assessment of images acquired during treatment verifies the accuracy of the delivered treatment and uncovers problems in patient set-up...
  56. pmc Escin, a pentacyclic triterpene, chemosensitizes human tumor cells through inhibition of nuclear factor-kappaB signaling pathway
    Kuzhuvelil B Harikumar
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Mol Pharmacol 77:818-27. 2010
    ....
  57. doi request reprint Does neoadjuvant treatment for gastric cancer patients with positive peritoneal cytology at staging laparoscopy improve survival?
    Brian Badgwell
    Department of Surgical Oncology, Unit 444, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, P O Box 301402, Houston, TX, 77030, USA
    Ann Surg Oncol 15:2684-91. 2008
    ....
  58. pmc Serum sTNF-R1, IL-6, and the development of fatigue in patients with gastrointestinal cancer undergoing chemoradiation therapy
    Xin Shelley Wang
    Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Brain Behav Immun 26:699-705. 2012
    ..0001). This longitudinal study suggests a role for over-expressed sTNF-R1 and IL-6 in the development of fatigue and other severe sickness symptoms during CXRT in patients with colorectal or esophageal cancer...
  59. ncbi request reprint Conformal radiotherapy of the dominant liver metastasis: a viable strategy for treatment of unresectable chemotherapy refractory colorectal cancer liver metastases
    Sunil Krishnan
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Am J Clin Oncol 29:562-7. 2006
    ..To evaluate the safety and efficacy of conformal radiotherapy (RT) of the dominant liver metastasis as palliative treatment of patients with unresectable colorectal cancer liver metastases...
  60. pmc Risk of second malignant neoplasm following proton versus intensity-modulated photon radiotherapies for hepatocellular carcinoma
    Phillip J Taddei
    Division of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Phys Med Biol 55:7055-65. 2010
    ..4% after PBT and 19.2% after IMRT. The results of this study suggest that using proton beams instead of photon beams for radiotherapy may reduce the risk of SMN incidence for some HCC patients...
  61. pmc Long-term survival and recurrence outcomes following surgery for distal rectal cancer
    Eric J Silberfein
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 17:2863-9. 2010
    ..The purpose of this study is to evaluate operative and pathologic factors associated with long-term survival and local recurrence outcomes in patients treated for distal rectal cancer...
  62. doi request reprint Long-term quality of life after radiotherapy for the treatment of anal cancer
    Prajnan Das
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston1515 Holcombe Boulevard, Unit 97, Houston, TX 77030, USA
    Cancer 116:822-9. 2010
    ..Radiotherapy is the current standard of care for patients with localized squamous cell cancer of the anal canal. The goal of the current study was to evaluate long-term quality of life (QoL) in patients after this treatment...
  63. doi request reprint Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer
    Amit Verma
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 14:2476-83. 2008
    ..Therefore, we examined therapeutic targeting of TG2 for inhibiting growth and metastasis of in vivo growing pancreatic ductal adenocarcinoma (PDAC) in nude mice...
  64. doi request reprint Proton radiotherapy for liver tumors: dosimetric advantages over photon plans
    Xiaochun Wang
    Department of Radiation Physics, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Med Dosim 33:259-67. 2008
    ..In conclusion, our study suggests the dosimetric benefits of proton radiotherapy over photon radiotherapy. These dosimetric advantages of proton plans may permit further dose escalation with lower risk of complications...
  65. pmc Capecitabine and timing of radiotherapy during preoperative chemoradiation for rectal cancer
    Manpreet Bedi
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX
    Gastrointest Cancer Res 1:44-8. 2007
    ..We retrospectively investigated whether the timing of radiotherapy affects rates of acute toxicity, pathologic response, and relapse in rectal cancer patients receiving capecitabine...
  66. ncbi request reprint The optimization of dose delivery for intraoperative high-dose-rate radiation therapy using curved HAM applicators
    A Sam Beddar
    Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Radiother Oncol 78:207-12. 2006
    ..To determine the effect of the curvature of Harrison-Anderson-Mick applicators on the dose distribution in high-dose-rate intraoperative radiation therapy (HDR-IORT)...
  67. doi request reprint Frequent loss of heterozygosity of chromosome 1q in esophageal adenocarcinoma: loss of chromosome 1q21.3 is associated with shorter overall survival
    Dipen M Maru
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 115:1576-85. 2009
    ..It was unclear whether this difference was due to loss of heterozygosity (LOH) or to other genetic alterations at this locus...
  68. pmc Gadolinium chloride augments tumor-specific imaging of targeted quantum dots in vivo
    Parmeswaran Diagaradjane
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    ACS Nano 4:4131-41. 2010
    ..This pretreatment strategy could have broad applicability across biomedical applications utilizing theranostic nanoparticles that are sequestered by the RES...
  69. doi request reprint Role of definitive radiation therapy in carcinoma of unknown primary in the abdomen and pelvis
    Patrick Kelly
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 82:2012-7. 2012
    ..In this study, we determined the effectiveness of radiation therapy in combination with chemotherapy in patients with CUP in the abdomen and pelvis...
  70. pmc Reirradiation to the abdomen for gastrointestinal malignancies
    Waqar Haque
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Radiat Oncol 4:55. 2009
    ..Our goal was to retrospectively determine rates of toxicity, freedom from local progression and overall survival in gastrointestinal cancer patients treated with reirradiation to the abdomen...
  71. ncbi request reprint Correlation between internal fiducial tumor motion and external marker motion for liver tumors imaged with 4D-CT
    A Sam Beddar
    Department of Radiation Physics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 67:630-8. 2007
    ..We investigated the correlation between the motions of an external marker and internal fiducials implanted in the liver for 8 patients undergoing respiratory-based computed tomography (four-dimensional CT [4D-CT]) procedures...
  72. pmc Targeting inflammatory pathways for tumor radiosensitization
    Amit Deorukhkar
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Biochem Pharmacol 80:1904-14. 2010
    ..We review recent data demonstrating the pivotal role played by inflammatory pathways in cancer progression and modulation of radiation response...
  73. pmc Modification of the cysteine residues in IkappaBalpha kinase and NF-kappaB (p65) by xanthohumol leads to suppression of NF-kappaB-regulated gene products and potentiation of apoptosis in leukemia cells
    Kuzhuvelil B Harikumar
    Cytokine Research Laboratory, Department of Experimental Therapeutics, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 113:2003-13. 2009
    ..Thus, our results show that modification of cysteine residues of IKK and p65 by XN leads to inhibition of the NF-kappaB activation pathway, suppression of antiapoptotic gene products, and potentiation of apoptosis in leukemia cells...
  74. pmc Neutrophil gelatinase-associated lipocalin: a novel suppressor of invasion and angiogenesis in pancreatic cancer
    Zhimin Tong
    Department of Gastroenterology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 68:6100-8. 2008
    ..Thus, NGAL is a potential suppressor of invasion and angiogenesis in advanced PaCa...
  75. ncbi request reprint Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): results of North Central Cancer Treatment Group trial 98-72-51
    Ravi D Rao
    Division of Medical Oncology, Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905 USA
    Int J Radiat Oncol Biol Phys 61:380-6. 2005
    ..To evaluate the efficacy of preradiotherapy (RT) chemotherapy with carmustine, cisplatin, and oral etoposide combined with RT in the treatment of newly diagnosed anaplastic astrocytoma...
  76. pmc Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma
    Ahmed O Kaseb
    Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 29:3892-9. 2011
    ..The study objective was to improve prognostic stratification of patients with HCC...
  77. ncbi request reprint Effect of combining anti-epidermal growth factor receptor antibody C225 and radiation on DU145 prostate cancer
    Matthew Wagener
    Department of Radiation Oncology, UT MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncol Rep 19:1071-7. 2008
    ..We drew the conclusion that the inhibition of EGFR augments the radiation killing of DU145 prostate cancer via a combination of cytostatic, necrotic and apoptotic mechanisms...
  78. ncbi request reprint Retrospective study of clinicopathologic features and prognosis of high-grade neuroendocrine carcinoma of the esophagus
    Dipen M Maru
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Am J Surg Pathol 32:1404-11. 2008
    ..031). There was no difference in prognosis between patients with large-cell NEC and those with small-cell neuroendocrine carcinoma. Esophageal NEC is an aggressive tumor, and patients with mix NEC have better outcome...
  79. ncbi request reprint Adjuvant therapy for ampullary carcinomas: the Mayo Clinic experience
    Sumita Bhatia
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Int J Radiat Oncol Biol Phys 66:514-9. 2006
    ..To determine the effects of adjuvant radiotherapy and chemotherapy for carcinoma of the ampulla of Vater...
  80. pmc Methodology for determining doses to in-field, out-of-field and partially in-field organs for late effects studies in photon radiotherapy
    Rebecca M Howell
    Graduate School of Biomedical Sciences, The University of Texas Health Science Center, Houston, TX 77030, USA
    Phys Med Biol 55:7009-23. 2010
    ..e. >5%. In such cases, we suggest supplementing calculated DVH data with measured dosimetric data using a volume-weighting technique to determine the mean dose...
  81. ncbi request reprint Intraoperative radiotherapy using a mobile electron LINAC: a retroperitoneal sarcoma case
    A Sam Beddar
    Department of Radiation Physics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Appl Clin Med Phys 6:95-107. 2005
    ..We also discuss the roles and coordination of multidisciplinary team members during IORT and the feasibility of using mobile LINACs for IORT...
  82. ncbi request reprint Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer
    Prajnan Das
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Am J Clin Oncol 29:219-24. 2006
    ..To identify predictive factors for locoregional recurrence (LR), distant metastasis (DM), and overall survival (OS) in patients treated with chemoradiation and surgery for rectal cancer...
  83. ncbi request reprint Targeting cell signaling pathways for drug discovery: an old lock needs a new key
    Bharat B Aggarwal
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Cell Biochem 102:580-92. 2007
    ..This review analyzes the shortcomings of rationally designed target-specific drugs against cancer cell signaling pathways and evaluates the available options for future drug development...
  84. ncbi request reprint Gastrointestinal complications associated with hepatic arterial Yttrium-90 microsphere therapy
    Ravi Murthy
    Division of Diagnostic Imaging, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    J Vasc Interv Radiol 18:553-61; quiz 562. 2007
    ..Our aim is to increase the understanding of the role of various imaging and preventative techniques in minimizing this undesired effect...
  85. ncbi request reprint Choroid plexus papillomas: a single institutional experience
    Sunil Krishnan
    Division of Radiation Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Neurooncol 68:49-55. 2004
    ..To determine the long-term outcome of resected choroid plexus papillomas (CPPs)...
  86. ncbi request reprint Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products
    Ajaikumar B Kunnumakkara
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Res 67:3853-61. 2007
    ..018 versus control). Overall, our results suggest that curcumin potentiates the antitumor effects of gemcitabine in pancreatic cancer by suppressing proliferation, angiogenesis, NF-kappaB, and NF-kappaB-regulated gene products...
  87. ncbi request reprint Back to basics: how natural products can provide the basis for new therapeutics
    Amit Deorukhkar
    The University of Texas MD Anderson Cancer Center, Department of Experimental Radiation Oncology, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Expert Opin Investig Drugs 16:1753-73. 2007
    ..This review focuses on the mechanism of action of key natural products and promising preclinical data on their efficacy as anticancer agents, as single agents and in combination with standard therapies...
  88. ncbi request reprint Combination of epidermal growth factor receptor targeted therapy with radiation therapy for malignant gliomas
    Sunil Krishnan
    Division of Radiation Oncology, Mayo Clinic and Foundation 200 First Street, SW, Rochester, MN 55905, USA
    Front Biosci 8:e1-13. 2003
    ....
  89. ncbi request reprint Radiosurgery for cranial base chordomas and chondrosarcomas
    Sunil Krishnan
    Division of Radiation Oncology, Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Neurosurgery 56:777-84; discussion 777-84. 2005
    ..To evaluate the efficacy and toxicity of radiosurgery in the treatment of cranial base chordoma and chondrosarcoma...
  90. ncbi request reprint Genetic and signaling pathway alterations in glioblastoma: relevance to novel targeted therapies
    Ravi D Rao
    Section of Medical Oncology, Department of Oncology, Mayo Clinic and Foundation 200 First Street, SW Rochester, MN 55905, USA
    Front Biosci 8:e270-80. 2003
    ..In this review, we will describe the most common genetic and signaling pathway alterations that have relevance to new drug development for the treatment of GBM...
  91. doi request reprint Imaging epidermal growth factor receptor expression in vivo: pharmacokinetic and biodistribution characterization of a bioconjugated quantum dot nanoprobe
    Parmeswaran Diagaradjane
    Department of Experimental Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:731-41. 2008
    ..To develop and validate an optical imaging nanoprobe for the discrimination of epidermal growth factor (EGF) receptor (EGFR)-overexpressing tumors from surrounding normal tissues that also expresses EGFR...